Overview

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an anthracycline-based chemotherapy regimen and be eligible for ASCT.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Ofatumumab
Rituximab